131 results
Page 5 of 7
424B5
iodepslo
9 Apr 21
Prospectus supplement for primary offering
12:00am
6-K
EX-99.1
1icxhq4b j6
6 Apr 21
VBL Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
3:33pm
6-K
EX-99.3
6uab5w
15 Jan 21
Ordinary Share Purchase Agreement
7:01am
424B5
3mykbxuypr dqqf
15 Jan 21
Prospectus supplement for primary offering
7:00am
424B3
y52f6bwdtr
16 Nov 20
Prospectus supplement
7:15am
6-K
u824rgjwx01463aya
16 Nov 20
Current report (foreign)
7:00am
6-K
EX-99.1
hiihvsc0zv5bw81l
13 Oct 20
VBL Therapeutics Announces Appointment of Marc Kozin as Vice Chairman of Board of Directors
8:30am
424B3
xz0vc1j v3qs
26 Aug 20
Prospectus supplement
5:21pm
6-K
ym3wtj eg06rfghu51
13 Aug 20
Current report (foreign)
7:00am
6-K
EX-99.1
yl0gihs
12 Aug 20
Current report (foreign)
8:45am
6-K
EX-99.2
g77tr
28 May 20
Notice of Annual General Meeting of Shareholders
9:14am
6-K
q2tyajr6fk
14 May 20
Current report (foreign)
7:25am
6-K
EX-10.1
g3gr8x73gga
12 May 20
Current report (foreign)
12:04pm
6-K
EX-99.1
r6qzuao6
12 May 20
Current report (foreign)
12:04pm
424B5
7wu0ci 7atcck
12 May 20
Prospectus supplement for primary offering
12:02pm
6-K
EX-99.1
hw4fpq7ouax4wz
11 May 20
VBL Therapeutics Announces $10.0 Million Registered Direct Offering
9:23am
6-K
EX-10.1
vpucphfs0ek 2tlm7c
11 May 20
VBL Therapeutics Announces $10.0 Million Registered Direct Offering
9:23am
424B5
8i8mnr u5
11 May 20
Prospectus supplement for primary offering
9:23am
6-K
EX-99.1
eso3639k0k
26 Mar 20
VBL Therapeutics Announces Positive Outcome of the Interim Analysis in the OVAL Phase 3 Ovarian Cancer Pivotal Study
8:08am